FDA approves new Alzheimer’s drug

The Food and Drug Administration has approved a new treatment for early Alzheimer’s.

The new drug may modestly slow the pace of cognitive decline early in the disease. The approval of the drug, lacanemab, is likely to generate considerable interest from both patients and physicians.

Janis Anderson has been a volunteer with the Mississippi Chapter of the Alzheimer Association for over eight years. The approval of the drug excites her because her father died from the disease seven years ago. “These drugs work best when the symptoms are caught in the early stages, and it gives them more time to be with loved ones and do the activities they enjoy, so it gives them a richer, fuller life.”

This drug does offer hope to patients everywhere, but comes with a steep price tag of over $26,000 a year.

Categories: Health